Free Trial Information
BioCentury | Mar 1, 2019
Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

...University in Union, N.J. Existing members are the Wellcome Trust, the California Life Sciences Institute, RTI...
Read More
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...rat and mouse studies identified a brain-penetrating GPR88 agonist that could help treat alcohol addiction RTI...
Read More
BioCentury | Aug 1, 2018
Distillery Therapeutics

Neurology

...July 16, 2018 doi:10.1021/acs.jmedchem.8b00566 CONTACT: Chunyang Jin, Research Triangle Institute, Research Triangle Park, N.C. email: cjin@rti.org Jaime...
Read More
BioCentury | May 9, 2018
Distillery Therapeutics

Hepatic

...mice, the compound had a brain-to-plasma ratio of 0.03 when administered orally. Next steps by RTI...
...April 24, 2018 doi:10.1021/acs.jmedchem.7b01820 CONTACT: Rangan Maitra, RTI International, Research Triangle Park, N.C. email: rmaitra@rti.org Jennie Walters RTI...
Read More
BioCentury | Mar 22, 2017
Financial News

Semma receives JDRF investment

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) said it received an undisclosed investment from the JDRF T1D Fund. Semma CEO Robert Millman told BioCentury that the investment, which took the form of a convertible...
Read More
BioCentury | Oct 6, 2016
Finance

X-ing out resistance

...at Tufts University School of Medicine. Additionally, regulatory and technical support will be available through RTI...
...Blood Institute (NHLBI), Bethesda, Md. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md. RTI...
Read More
BioCentury | Jul 25, 2016
Finance

That was then; this is now

...Xetra:BAYN) 7/27 Pre €2.00 €1.98 1% The Medicines Co. (NASDAQ:MDCO) 7/27 Pre -$1.16 -$0.71 NA RTI...
Read More
BioCentury | Feb 15, 2016
Finance

Breaking from tradition

...EPS est 4Q14 EPS Expected chg Baxalta Inc. (NYSE:BXLT) (A) 2/16 Pre $0.56 NA NA RTI...
Read More
BioCentury | Nov 2, 2015
Company News

HEI, Otologic deal

HEI granted Otologic exclusive, worldwide rights to develop and commercialize an inner ear sensory hair cell regeneration technology. The technology uses small interfering nucleic acids and small molecules to regenerate lost hair cells in the...
Read More
BioCentury | Jul 28, 2015
Clinical News

Bellerophon plummets on BCM data

...an alternative development path for BCM that "could involve use in combination with emerging tissue regeneration technologies...
Read More
Items per page:
1 - 10 of 59
BioCentury | Mar 1, 2019
Company News

CARB-X adds new members to increase number of funded antimicrobial research projects

...University in Union, N.J. Existing members are the Wellcome Trust, the California Life Sciences Institute, RTI...
Read More
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

...rat and mouse studies identified a brain-penetrating GPR88 agonist that could help treat alcohol addiction RTI...
Read More
BioCentury | Aug 1, 2018
Distillery Therapeutics

Neurology

...July 16, 2018 doi:10.1021/acs.jmedchem.8b00566 CONTACT: Chunyang Jin, Research Triangle Institute, Research Triangle Park, N.C. email: cjin@rti.org Jaime...
Read More
BioCentury | May 9, 2018
Distillery Therapeutics

Hepatic

...mice, the compound had a brain-to-plasma ratio of 0.03 when administered orally. Next steps by RTI...
...April 24, 2018 doi:10.1021/acs.jmedchem.7b01820 CONTACT: Rangan Maitra, RTI International, Research Triangle Park, N.C. email: rmaitra@rti.org Jennie Walters RTI...
Read More
BioCentury | Mar 22, 2017
Financial News

Semma receives JDRF investment

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) said it received an undisclosed investment from the JDRF T1D Fund. Semma CEO Robert Millman told BioCentury that the investment, which took the form of a convertible...
Read More
BioCentury | Oct 6, 2016
Finance

X-ing out resistance

...at Tufts University School of Medicine. Additionally, regulatory and technical support will be available through RTI...
...Blood Institute (NHLBI), Bethesda, Md. National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Md. RTI...
Read More
BioCentury | Jul 25, 2016
Finance

That was then; this is now

...Xetra:BAYN) 7/27 Pre €2.00 €1.98 1% The Medicines Co. (NASDAQ:MDCO) 7/27 Pre -$1.16 -$0.71 NA RTI...
Read More
BioCentury | Feb 15, 2016
Finance

Breaking from tradition

...EPS est 4Q14 EPS Expected chg Baxalta Inc. (NYSE:BXLT) (A) 2/16 Pre $0.56 NA NA RTI...
Read More
BioCentury | Nov 2, 2015
Company News

HEI, Otologic deal

HEI granted Otologic exclusive, worldwide rights to develop and commercialize an inner ear sensory hair cell regeneration technology. The technology uses small interfering nucleic acids and small molecules to regenerate lost hair cells in the...
Read More
BioCentury | Jul 28, 2015
Clinical News

Bellerophon plummets on BCM data

...an alternative development path for BCM that "could involve use in combination with emerging tissue regeneration technologies...
Read More
Items per page:
1 - 10 of 59